Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study

2021 ◽  
Author(s):  
Almudena Callejo ◽  
Sara Faouzi ◽  
Olivier Bouché ◽  
François Bertucci ◽  
Thomas Chevalier ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors ◽  
Exon 9 ◽  
Retrospective Multicenter Study

scholarly journals Nomogram for Predicting Risk of Esophagogastric Junction (EGJ) Resection During Laparoscopic Resection of Gastrointestinal Stromal Tumors in EGJ: A Retrospective Multicenter Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Yuting Xu ◽  
Lijie Luo ◽  
Xingyu Feng ◽  
Yensheng Zheng ◽  
Tao Chen ◽  
...  
Keyword(s):  
Laparoscopic Surgery ◽  
Multicenter Study ◽  
Tumor Size ◽  
Gastrointestinal Stromal Tumors ◽  
Esophagogastric Junction ◽  
Distant Metastases ◽  
Stromal Tumors ◽  
Surgical Methods ◽  
Medical University ◽  
Retrospective Multicenter Study

Background: The established criteria for determining whether to excise the cardia during laparoscopic surgery for gastrointestinal stromal tumors in the esophagogastric junction (EGJ-GISTs) remain controversial. This retrospective multicenter study was conducted to develop a nomogram for predicting the risk of the cardia excision during laparoscopic surgery for EGJ-GISTs.Material and Methods: We reviewed data from 2,127 gastric-GISTs (g-GISTs) patients without distant metastases in four hospital between June 2012 and June 2020. Of those, according to the including criteria, 184 patients [Guangdong Provincial Hospital of Chinese Medicine (n = 81), Nanfang Hospital of Southern Medical University (n = 60), Guangdong General Hospital (n = 34), and The Third Affiliated Hospital of Southern Medical University (n = 9)] with EGJ-GISTs were identified and included in this study. Factors contributing to risk of cardia excision were identified and used to create a nomogram. Nomogram performance was assessed using a bootstrapped concordance index (c-index) and calibration plots.Results: According to the multivariate analysis, the distance from the margin of the tumor to the esophagogastric line (EG-line) (cm) (OR = 0.001, 95% CI: 0.00001~0.056, P = 0.001) and tumor size (cm) (OR = 14.969, 95% CI: 1.876~119.410, P = 0.011) were significantly related to likelihood of cardia structure excision in laparoscopic surgery for EGJ-GISTs. These two factors were used to generate a nomogram for predicting risk of cardia excision using a logistic regression model; a bootstrapped C-index of 0.988 (calibrated C-index = 0.987) indicated strong predictive ability, with broad calibration.Conclusions: This nomogram based on distance from tumor margin to EG-line and tumor size may serve as a tool for predicting risk of cardia damage during laparoscopic removal of EGJ-GISTs to aid in selection of surgical methods and preoperative neoadjuvant therapy.

scholarly journals Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases

2008 ◽  
Vol 21 (4) ◽  
pp. 476-484 ◽  
Author(s):  
Jerzy Lasota ◽  
Christopher L Corless ◽  
Michael C Heinrich ◽  
Maria Debiec-Rychter ◽  
Raf Sciot ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors ◽  
Clinicopathologic Profile

scholarly journals Gastrointestinal Stromal Tumors of the Stomach with Kit Exon 9 Mutations Mostly Present with a Favorable Prognosis

2012 ◽  
Vol 23 ◽  
pp. ix481
Author(s):  
E. Wardelmann ◽  
H. Löser ◽  
W. Jeske ◽  
S. Merkelbach-Bruse ◽  
P. Hohenberger ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors ◽  
Favorable Prognosis ◽  
Exon 9

Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 10550-10550 ◽  
Author(s):  
P. Hohenberger ◽  
O. Oladeji ◽  
T. Licht ◽  
A. Dimitrakopoulou-Strauss ◽  
J. Jakob ◽  
...  
Keyword(s):  
Tumor Size ◽  
Gastrointestinal Stromal Tumors ◽  
Organ Preservation ◽  
Locally Advanced ◽  
Response To Therapy ◽  
Long Term Results ◽  
Stromal Tumors ◽  
Local Recurrences ◽  
Tumor Boards ◽  
Exon 9

10550 Background: We assessed the outcome of patients with locally advanced gastrointestinal stromal tumors (GIST) undergoing preoperative therapy with imatinib. Methods: 36 patients with biopsy proven GIST (23 f, 13 m, median age 58 (27–85) yrs, 31 primary tumors, 5 local recurrences) of the esophagus/EGJ (n=5), stomach (n=17), duodenum (n=2), small bowel (n=3), or rectum (n=9) were treated with imatinib 400mg/d for 6 mos. preop. Six pts had been found unresectable at exploratory lap. and no pt. had signs of metastases on CT/MRI and/or FDG-PET. Average tumor size was 10.5 cm (4–28 cm). According to Consensus two tumors were low risk, 11 intermediate, and 23 were high risk for aggressive behaviour. 33 pts were symptomatic. Extent of surgery, local outcome, morbidity and response to therapy were analyzed; median follow-up is 22 mos. Results: Median treatment duration was 11 mos. (range 2–31 mos). Successful dose adjustment for exon 9 mutation to 800 mg imatinib/d was used in two pts. 33 pts. completed the treatment schedule, two died from unrelated disease, another one had to be operated for tumor rupture. Of the remaining 33, median tumor size shrank to 55 mm. Two elderly patients refused surgery and continued with the drug; one pt. was found still unresectable. Complete tumor removal was possible in 28 pts without operative mortality, but two pts showed previously undetected peritoneal spread (R2 resection). Histologically, one pCR and 11 near CR/good PRs were found. The extent of resection found 5 of 6 inoperable pts now resectable and in 21/25 pts a less extensive procedure could be performed in comparison to recommendations by previous tumor boards (segmental gastric resection for gastrectomy, avoidance of pancreatectomy, transanal resection instead of colo-anal anastomosis). Two local recurrences were detected at 31 and 44 mos. postop. Conclusions: Locoregionally advanced GIST can be treated successfully with upfront imatinib at 400mg/ (800 mg in exon 9 mutation). Substantial tumor shrinkage facilitates radical but conservative surgery and results in organ-preservation in the overwhelming majority of patients. PET monitoring proved very helpful and added to CT/MRI evaluation. Long-term results on survival and metastatic spread have to be awaited. [Table: see text]

scholarly journals Endoscopic versus laparoscopic resection of gastric gastrointestinal stromal tumors: a multicenter study

Oncotarget ◽  
2016 ◽  
Vol 8 (7) ◽  
pp. 11259-11267 ◽  
Author(s):  
Wei-Jie Dai ◽  
Gao Liu ◽  
Min Wang ◽  
Wen-Jie Liu ◽  
Wei Song ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Gastrointestinal Stromal Tumors ◽  
Laparoscopic Resection ◽  
Stromal Tumors

The real world outcomes of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e23524-e23524
Author(s):  
Piotr Rutkowski ◽  
Marcin Zietek ◽  
Bozena Cybulska-Stopa ◽  
Joanna Streb ◽  
Stanislaw Gluszek ◽  
...  
Keyword(s):  
Clinical Trials ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Real World ◽  
Gastrointestinal Stromal Tumors ◽  
Disease Relapse ◽  
Adjuvant Imatinib ◽  
Stromal Tumors ◽  
Exon 9 ◽  
Exon 11

e23524 Background: The real-world data on outcomes of adjuvant therapy in high-risk gastrointestinal stromal tumors (GIST) are very limited. Methods: We have analyzed the data of 107 consecutive patients (52 male, 56 female) with GIST after resection treated with adjuvant imatinib (for planned 3 years with initial dose 400 mg daily, started not later than 4 months after operation) in 6 oncological centers in 2013-2018. All patients were required to have high risk of recurrence (at least 50% according to NCCN/AFIP criteria), known mutational status to exclude PDGFRA D842V mutants and KIT/PDGFRA-wild type cases from therapy. Median follow-up time was 24 months. Results: The most common primary localization of GIST was small bowel (63 patients; 59%), followed by the stomach (40 patients; 37%). The majority of GIST cases harbored exon 11 KIT mutations (88 cases, 82%), 11 cases had exon 9 KIT mutations (10%), 8 had other KIT/PDGFRA mutations potentially sensitive to imatinib. Thirty three patients (31%) finished 3-year adjuvant imatinib therapy as planned, 59 (55%) still continue therapy, 4 (4%) patients had finished adjuvant therapy prematurely due to toxicity, 6 (6%) due to disease progression on treatment and 5 (4%) due to other reasons. The disease relapse was detected in 16 patients, of them in 4 cases in exon 9 KIT mutants (36%), and 10 cases in patients with exon 11 KIT mutations (11%) [p < 0.05]. Estimated 4-year relapse-free survival (RFS) rate is 78%. Conclusions: The early results of adjuvant therapy with imatinib in routine practice outside clinical trials in high-risk mutation-drive GIST patients only confirm high efficacy of this therapy with better tolerability than in clinical trials. Moreover, overrepresentation of exon 9 KIT mutants in a group of patients with disease relapse may indicate that standard 400 mg dose in adjuvant treatment is not sufficient for prevention of disease relapse.

Clinical significance of performing 18F-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study

2009 ◽  
Vol 23 (5) ◽  
pp. 459-464 ◽  
Author(s):  
Tomohiro Kaneta ◽  
Shoki Takahashi ◽  
Hiroshi Fukuda ◽  
Yukiko Arisaka ◽  
Noboru Oriuchi ◽  
...  
Keyword(s):  
Clinical Significance ◽  
Multicenter Study ◽  
Fdg Pet ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors ◽  
18F Fdg

Subgroups of patients with very large gastrointestinal stromal tumors with distinct prognoses: A multicenter study

2013 ◽  
Vol 109 (2) ◽  
pp. 67-70 ◽  
Author(s):  
Noriko Wada ◽  
Yukinori Kurokawa ◽  
Toshirou Nishida ◽  
Tsuyoshi Takahashi ◽  
Takahiro Toyokawa ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors

scholarly journals Unraveling the spectrum of KIT mutations in gastrointestinal stromal tumors: An Indian Tertiary Cancer Center Experience

2017 ◽  
Vol 06 (03) ◽  
pp. 113-117 ◽  
Author(s):  
Trupti Pai ◽  
Munita Bal ◽  
Omshree Shetty ◽  
Mamta Gurav ◽  
Vikas Ostwal ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Complete Analysis ◽  
Cancer Center ◽  
Kit Mutation ◽  
Stromal Tumors ◽  
Molecular Alterations ◽  
Kit Gene ◽  
Exon 9 ◽  
Substitution Mutations ◽  
Exon 11

Abstract Background: Primary mutations in the KIT gene are the driving force for gastrointestinal stromal tumors (GIST) tumorigenesis. Predictive role of KIT mutation status aids oncologists in patient management. There is a paucity of comprehensive data on the frequency of mutations in the KIT gene in GIST affecting Indian patients. The aims of this study were to determine the frequency and spectrum of molecular alterations affecting the KIT gene and assess their association with clinicopathologic features in a cohort of patients of GIST. Materials and Methods: Morphological and immunohistochemically confirmed GIST cases (n = 114) accessioned from August 2014-June 2015 were analyzed for mutations in KIT exons 9, 11, 13, and 17 and subjected to Sanger sequencing onto the ABI 3500 Genetic Analyzer. The sequences were analyzed using sequence analysis software: SeqScape® and Chromas Lite. Results: KIT mutations were seen in 70% of cases and the majority of KIT mutations involved exon 11 (57%), followed by exon 9 (10%), exon 13 (3%), and exon 17 (1%). Most common exon 11 mutations were in-frame deletions (61.4%) followed by substitution mutations (19.3%). Exon 9 mutations showed identical duplication of Ala-Tyr at codons 502–503. Simultaneous mutations affecting exon 11 and 13 were discovered. Novel variations, namely, p.Q556E (c.1666C>G), p.Q556dup (c.1666_1668dupCAG), p.K558_V559delinsS (c.1672_1677delAAGGTTinsAGT), p.Y503_F504insTY (c.1509_1510insACCTAT), and p.K642R (c.1925A>G) involving exons 11, 9, and 13, respectively, were observed. Interpretation and Conclusions: First study with complete analysis of all 4 exons of KIT (exons 9, 11, 13, and 17) in Indian GIST patients. Along with well-described KIT mutations, several rare double mutations as well as novel alterations were reported in this series.

Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 10507-10507 ◽  
Author(s):  
Margaret von Mehren ◽  
Suzanne George ◽  
Michael C. Heinrich ◽  
Scott Schuetze ◽  
Martin G. Belinsky ◽  
...  
Keyword(s):  
Phase Ii ◽  
Multicenter Study ◽  
Gastrointestinal Stromal Tumors ◽  
Wild Type ◽  
Stromal Tumors
Sign in / Sign up

Export Citation Format

Share Document